Yesterday the Supreme Court ruled unanimously that human genes cannot be patented, but synthetic DNA is still patentable.
The case was brought against Myriad Genetics, which owned patents on two naturally occurring genes associated with breast and ovarian cancer. Those patents allowed the company to exclusively administer breast cancer tests and set the price. According to the plaintiffs, they set the price too high.
Sandra Park, lead attorney for the plaintiffs, explains.